Increases in drug prices are of concern to worldwide health systems

By HEOR Staff Writer

March 17, 2023

In surveys of ISPOR members, drug pricing was revealed to be a major concern, and one of the top 10 health economics and outcomes research issues influencing the availability of innovative treatments and healthcare decisions.

Despite the fascinating ways that different research studies proposed to understand the puzzle of drug pricing, it is evident that drug prices must factor in the research uncertainties and other costs in addition to the cost of clinical trials and production and should be set to yield an acceptable return on investment.

There has been a lot of discussion about the fairness of drug pricing. The concept is multifaceted, and when discussing it, drug characteristics and market forces must be included. This conversation is further complicated by the lack of transparency in drug pricing and the rise in drug prices.

It is likely that the debate will persist.

Reference url

Recent Posts

NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Surgery

By João L. Carapinha

September 18, 2025

The NICE kidney cancer guideline represents a major shift in how renal cell carcinoma is diagnosed and managed in the UK. How does this guideline change the standard of kidney cancer care? By emphasizing more accurate diagnosis—especially the targeted use of kidney biopsies—it aims to avoid unnec...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascular Perks

By HEOR Staff Writer

September 16, 2025

Novo Nordisk’s oral semaglutide (Rybelsus®) has received a significant label update from the European Medicines Agency (EMA). It is now the first and only oral glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved in the EU for type 2 diabetes with proven cardiovascular benefits. This deci...